On March 18, 2026, REGENXBIO Inc. agreed to pay $10 million to GlaxoSmithKline to settle a dispute regarding underpaid sublicense fees. This agreement resolves past and certain future claims related to their License Agreement initiated in 2009.
AI Assistant
REGENXBIO INC
2026
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.